BerandaIMMP • NASDAQ
add
Immutep Ltd - ADR
$1,93
Setelah Jam Perdagangan Normal:(0,26%)-0,0050
$1,92
Tutup: 22 Nov, 19.02.12 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$1,84
Rentang hari
$1,87 - $1,96
Rentang tahun
$1,66 - $3,34
Kapitalisasi pasar
282,04Â jt USD
Volume Rata-Rata
101,17Â rb
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (AUD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 865,57Â rb | -4,89% |
Biaya operasional | 2,03Â jt | -10,92% |
Laba bersih | -10,74Â jt | -11,49% |
Margin laba bersih | -1,24Â rb | -17,23% |
Penghasilan per saham | — | — |
EBITDA | -11,21Â jt | -17,52% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (AUD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 181,88Â jt | 47,37% |
Total aset | 201,58Â jt | 36,71% |
Total liabilitas | 12,06Â jt | 9,82% |
Total ekuitas | 189,52 jt | — |
Saham yang beredar | 1,45 M | — |
Harga terhadap nilai buku | 14,15 | — |
Tingkat pengembalian aset | -14,53% | — |
Tingkat pengembalian modal | -15,32% | — |
Arus Kas
Perubahan kas bersih
| (AUD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -10,74Â jt | -11,49% |
Kas dari operasi | -8,19Â jt | 30,16% |
Kas dari investasi | -10,30Â jt | -87.445,92% |
Kas dari pembiayaan | 47,81Â jt | 25,58% |
Perubahan kas bersih | 29,03Â jt | 5,47% |
Arus kas bebas | -6,10Â jt | -44,31% |
Tentang
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Didirikan
2001
Situs
Karyawan
19
